Lazzaro Medical develops a robotically assisted Minimally Invasive Tracheal Repair (MITR™) procedure centered on its patented LM Scaffold System™ to treat tracheobronchomalacia (TBM). The company is advancing R&D, verification and validation, preclinical testing, and regulatory activities to bring the system to market. Lazzaro has additional patents filed to expand its TBM diagnostic and treatment platform. It cites collaborations with Mayo Clinic and strategic funding from partners including Northwell Health and the Colorado Office of Economic Development and International Trade (OEDIT), plus support from a leading robotic-systems manufacturer. The company was founded in 2019 and is based in Boulder, Colorado. Management emphasizes accelerating availability of a less invasive, lower-risk repair option for underdiagnosed TBM patients. Lazzaro Medical develops a platform of non-invasive, robotic procedures, devices, and diagnostics aimed at restoring healthy breathing for people with tracheal and bronchial conditions, including TBM. The company emphasizes a less invasive repair option and aims to raise awareness of TBM as an under- or misdiagnosed disease. Proceeds from the recent financing will be used to prepare a 510(k) FDA submission and support a forthcoming commercial launch. Future product and program plans include a diagnostic endoscope, comprehensive training programs for thoracic surgeons, and additional devices to simplify the procedure. Financially, the company has secured strategic investor support and non-dilutive grant funding to advance regulatory and commercialization milestones.

Total raised

$3M

Funding rounds

2

Latest round

Grant

Latest activity

Jun 2024